Amgen Inc. Shares Trade Slightly Lower Amid Positive Market Momentum
Amgen Inc. (NASDAQ: AMGN) closed its trading session on Thursday, October 22, 2026, down 0.14 % to a closing price of USD 449.04 per share. The decline occurred within a broader context of modest gains across the Dow Jones Industrial Average, where Amgen was among the better‑performing constituents, alongside peers such as 3M, UnitedHealth Group, and Merck.
Trading and Market Overview
- Current trading price: USD 449.04
- Market capitalization: USD 237.3 billion
- Shares outstanding: 540.6 million
- Volume traded in last 24 hours: USD 1.1 billion worth of shares
- Year‑to‑date change: 6.85 % increase from the previous month‑end level
- Simple moving average (200 days): USD 370.53
- 52‑week high: USD 447.03 (recorded 08/25/2026)
- 52‑week low: USD 288.00 (recorded 10/31/2025)
The company’s shares moved within a narrow range, reflecting a stable market environment for biotechnology stocks. Amgen’s 200‑day moving average suggests that the stock is trading well above its long‑term average, indicating a bullish trend in the medium term.
Recent Corporate Activity
Amgen announced a planned investor webcast focused on its oncology portfolio, scheduled to precede the European Society of Medical Oncology Congress later in the week. The webcast is intended to provide stakeholders with updated insights into Amgen’s therapeutic developments and to reinforce the company’s engagement with the investment community.
Performance of Related Stocks in the Last 24 Hours
| Ticker | Current Price | % Move | Market Cap | P/E Ratio | Key Event |
|---|---|---|---|---|---|
| TXN (Texas Instruments) | USD 279.29 | +2.47 % | USD 253.7 billion | 42.55 | Q3 earnings beat, positive outlook |
| CRWD (CrowdStrike) | USD 238.61 | +5.26 % | USD 245.1 billion | 6,191.6 | Partnership with NVIDIA for AI‑native security |
| GS (Goldman Sachs) | USD 891.55 | +2.25 % | USD 267.9 billion | 12.73 | Filing of 424(b)(2) prospectus for medium‑term notes |
| GEV (Ge Vernova) | USD 822.47 | +4.00 % | USD 237.1 billion | 25.55 | Involvement in Saskatchewan nuclear power initiative |
| TMO (Thermo Fisher Scientific) | USD 682.37 | +0.97 % | USD 254.2 billion | 37.1 | Q3 results beat expectations, guidance maintained |
These movements illustrate a sector‑wide trend of modest gains, driven primarily by earnings reports and strategic partnerships rather than macroeconomic catalysts.
Company Profile
Amgen Inc. is an independent biotechnology firm focused on the discovery, development, manufacturing, and marketing of drugs for serious illnesses. The company’s portfolio centers on human therapeutics, leveraging cellular and molecular biology to develop innovative medicines. Amgen is listed on the Nasdaq stock exchange and maintains a global presence in research and development, manufacturing, and commercialization of its products.
For more information, visit the company’s website at www.amgen.com .
